FI72515C - Foerfarande foer framstaellning av terapeutiskt anvaendbara 2,4-diacetyl-5-(3-alkylamino-2-hydroxipropyloxi) bensfuraner. - Google Patents
Foerfarande foer framstaellning av terapeutiskt anvaendbara 2,4-diacetyl-5-(3-alkylamino-2-hydroxipropyloxi) bensfuraner. Download PDFInfo
- Publication number
- FI72515C FI72515C FI823707A FI823707A FI72515C FI 72515 C FI72515 C FI 72515C FI 823707 A FI823707 A FI 823707A FI 823707 A FI823707 A FI 823707A FI 72515 C FI72515 C FI 72515C
- Authority
- FI
- Finland
- Prior art keywords
- diacetyl
- therapeutic
- compound
- isoprenaline
- alkylamino
- Prior art date
Links
- 238000000034 method Methods 0.000 title description 6
- 230000001225 therapeutic effect Effects 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims description 19
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 2
- 239000004593 Epoxy Substances 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 abstract description 8
- 229940097320 beta blocking agent Drugs 0.000 abstract description 8
- 150000003839 salts Chemical class 0.000 abstract description 5
- 239000002253 acid Substances 0.000 abstract description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 14
- 229960001317 isoprenaline Drugs 0.000 description 14
- 230000000694 effects Effects 0.000 description 10
- PMNVZOLFGAIFIF-UHFFFAOYSA-N 1-[4-acetyl-5-[3-(tert-butylamino)-2-hydroxypropoxy]-1-benzofuran-2-yl]ethanone;hydrochloride Chemical compound Cl.CC(C)(C)NCC(O)COC1=CC=C2OC(C(=O)C)=CC2=C1C(C)=O PMNVZOLFGAIFIF-UHFFFAOYSA-N 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 7
- JGAPGCLZGXMAGI-UHFFFAOYSA-N 1-(4-acetyl-5-hydroxy-1-benzofuran-2-yl)ethanone Chemical compound OC1=CC=C2OC(C(=O)C)=CC2=C1C(C)=O JGAPGCLZGXMAGI-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 5
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 241000700198 Cavia Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 230000003276 anti-hypertensive effect Effects 0.000 description 3
- 210000001715 carotid artery Anatomy 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- LVLAYPUCBRWYIZ-UHFFFAOYSA-N 1-[4-acetyl-5-[3-(tert-butylamino)-2-hydroxypropoxy]-1-benzofuran-2-yl]ethanone Chemical compound CC(C)(C)NCC(O)COC1=CC=C2OC(C(=O)C)=CC2=C1C(C)=O LVLAYPUCBRWYIZ-UHFFFAOYSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 208000009079 Bronchial Spasm Diseases 0.000 description 2
- 208000014181 Bronchial disease Diseases 0.000 description 2
- 206010006482 Bronchospasm Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000005240 left ventricle Anatomy 0.000 description 2
- 229940105631 nembutal Drugs 0.000 description 2
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 2
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 1
- IDZQAKIKWQJSHP-UHFFFAOYSA-N 1-[4-acetyl-5-[2-hydroxy-3-(propan-2-ylamino)propoxy]-1-benzofuran-2-yl]ethanone Chemical compound CC(C)NCC(O)COC1=CC=C2OC(C(C)=O)=CC2=C1C(C)=O IDZQAKIKWQJSHP-UHFFFAOYSA-N 0.000 description 1
- -1 2-petanone Chemical compound 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AIJULSRZWUXGPQ-UHFFFAOYSA-N Methylglyoxal Chemical compound CC(=O)C=O AIJULSRZWUXGPQ-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000000923 adrenergic beta-3 receptor antagonist Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229940034740 atropine injection Drugs 0.000 description 1
- WIRUZQNBHNAMAB-UHFFFAOYSA-N benzene;cyclohexane Chemical compound C1CCCCC1.C1=CC=CC=C1 WIRUZQNBHNAMAB-UHFFFAOYSA-N 0.000 description 1
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 description 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001907 coumarones Chemical class 0.000 description 1
- VGHOWOWLIXPTOA-UHFFFAOYSA-N cyclohexane;toluene Chemical compound C1CCCCC1.CC1=CC=CC=C1 VGHOWOWLIXPTOA-UHFFFAOYSA-N 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- GKIPXFAANLTWBM-UHFFFAOYSA-N epibromohydrin Chemical compound BrCC1CO1 GKIPXFAANLTWBM-UHFFFAOYSA-N 0.000 description 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940090044 injection Drugs 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical group CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 231100001160 nonlethal Toxicity 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 150000002924 oxiranes Chemical class 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8120471A FR2515649A1 (fr) | 1981-10-30 | 1981-10-30 | Nouveaux derives appartenant a la famille des 3-amino-1-heteroaryloxy-2-propanols, utilisation en therapeutique et procede de preparation |
| FR8120471 | 1981-10-30 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| FI823707A0 FI823707A0 (fi) | 1982-10-29 |
| FI823707L FI823707L (fi) | 1983-05-01 |
| FI72515B FI72515B (fi) | 1987-02-27 |
| FI72515C true FI72515C (fi) | 1987-06-08 |
Family
ID=9263594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI823707A FI72515C (fi) | 1981-10-30 | 1982-10-29 | Foerfarande foer framstaellning av terapeutiskt anvaendbara 2,4-diacetyl-5-(3-alkylamino-2-hydroxipropyloxi) bensfuraner. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US4485111A (OSRAM) |
| EP (1) | EP0078735B1 (OSRAM) |
| JP (1) | JPS58121287A (OSRAM) |
| AT (1) | ATE15669T1 (OSRAM) |
| AU (1) | AU550498B2 (OSRAM) |
| CA (1) | CA1197516A (OSRAM) |
| DE (1) | DE3266420D1 (OSRAM) |
| DK (1) | DK481082A (OSRAM) |
| ES (1) | ES516988A0 (OSRAM) |
| FI (1) | FI72515C (OSRAM) |
| FR (1) | FR2515649A1 (OSRAM) |
| GR (1) | GR76240B (OSRAM) |
| IE (1) | IE54054B1 (OSRAM) |
| NO (1) | NO157419C (OSRAM) |
| NZ (1) | NZ202326A (OSRAM) |
| ZA (1) | ZA827930B (OSRAM) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1503510A (fr) * | 1962-11-23 | 1967-12-01 | Ici Ltd | Composés naphtaléniques et leur procédé de fabrication |
| NL300664A (OSRAM) * | 1962-11-23 | |||
| US3853923A (en) * | 1971-05-13 | 1974-12-10 | Kakenyaku Kako Kk | 2-substituted-(2-hydroxy-3-lower alkaminopropoxy)-benzofurans |
-
1981
- 1981-10-30 FR FR8120471A patent/FR2515649A1/fr active Granted
-
1982
- 1982-10-22 IE IE2552/82A patent/IE54054B1/en unknown
- 1982-10-25 EP EP82401959A patent/EP0078735B1/fr not_active Expired
- 1982-10-25 DE DE8282401959T patent/DE3266420D1/de not_active Expired
- 1982-10-25 AT AT82401959T patent/ATE15669T1/de not_active IP Right Cessation
- 1982-10-26 GR GR69643A patent/GR76240B/el unknown
- 1982-10-27 CA CA000414274A patent/CA1197516A/en not_active Expired
- 1982-10-28 US US06/437,210 patent/US4485111A/en not_active Expired - Fee Related
- 1982-10-29 ES ES516988A patent/ES516988A0/es active Granted
- 1982-10-29 NZ NZ202326A patent/NZ202326A/en unknown
- 1982-10-29 AU AU90082/82A patent/AU550498B2/en not_active Ceased
- 1982-10-29 ZA ZA827930A patent/ZA827930B/xx unknown
- 1982-10-29 FI FI823707A patent/FI72515C/fi not_active IP Right Cessation
- 1982-10-29 NO NO823611A patent/NO157419C/no unknown
- 1982-10-29 DK DK481082A patent/DK481082A/da not_active Application Discontinuation
- 1982-10-30 JP JP57191729A patent/JPS58121287A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DK481082A (da) | 1983-05-01 |
| IE822552L (en) | 1983-04-30 |
| NO157419C (no) | 1988-03-16 |
| CA1197516A (en) | 1985-12-03 |
| FI823707A0 (fi) | 1982-10-29 |
| ZA827930B (en) | 1983-08-31 |
| IE54054B1 (en) | 1989-05-24 |
| AU9008282A (en) | 1983-05-05 |
| FI72515B (fi) | 1987-02-27 |
| GR76240B (OSRAM) | 1984-08-04 |
| FR2515649A1 (fr) | 1983-05-06 |
| EP0078735A1 (fr) | 1983-05-11 |
| ES8307782A1 (es) | 1983-08-01 |
| NO157419B (no) | 1987-12-07 |
| US4485111A (en) | 1984-11-27 |
| NO823611L (no) | 1983-05-02 |
| ATE15669T1 (de) | 1985-10-15 |
| ES516988A0 (es) | 1983-08-01 |
| DE3266420D1 (en) | 1985-10-24 |
| NZ202326A (en) | 1985-08-30 |
| AU550498B2 (en) | 1986-03-20 |
| EP0078735B1 (fr) | 1985-09-18 |
| FI823707L (fi) | 1983-05-01 |
| JPS58121287A (ja) | 1983-07-19 |
| FR2515649B1 (OSRAM) | 1984-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4018895A (en) | Aryloxyphenylpropylamines in treating depression | |
| US4314081A (en) | Arloxyphenylpropylamines | |
| US4194009A (en) | Aryloxyphenylpropylamines for obtaining a psychotropic effect | |
| US3309406A (en) | 1-t-butylamino-3-phenoxy-2-propanols | |
| FR2479825A1 (fr) | Benzodioxanne 1,4 methoxy-2 propanolamines, leur preparation et leur application en tant que medicaments | |
| US5190961A (en) | Thiourea derivatives and antimicrobial agent and antulcer agent containing the same | |
| FI72515B (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara 2,4-diacetyl-5-(3-alkylamino-2-hydroxipropyloxi) bensfuraner. | |
| CH617689A5 (OSRAM) | ||
| KR950001040B1 (ko) | 티오우레아 유도체 및 이를 함유하는 항균제 및 항궤양제 | |
| US3959283A (en) | Amino-derivatives of 1,4-benzodioxan | |
| Biel et al. | Bronchodilators, N-Substituted Derivatives of 1-(3', 4'-Dihydroxyphenyl)-2-aminoethanol (Arterenol) | |
| SE452005B (sv) | Estrar av alkoxi-acylderivat av karnitin och farmaceutiska kompositioner innehallande desamma | |
| IE43745B1 (en) | Disubstituted phenol ethers of 3-amino-2-hydroxypropane,processes for their preparation and their use as medicaments | |
| CS250682B2 (en) | Method of s(-)-3-(3-acetyl-4-/3-tertiary butylamino-2-hydroxypropoxy/-phenyl)-1,1-diethylurea production | |
| HU181736B (en) | Process for producing new 3-amino-1-benzoxepine derivatives | |
| KR850000628B1 (ko) | 알콕시-아실 카트니틴의 제조방법 | |
| US4207319A (en) | Thienyl or furyl phenyl O-hetero amino alkyl oximes and use thereof | |
| US4757067A (en) | Therapeutic application of N-substituted 2-aminomethylene-1,3-indanediones | |
| US20250205221A1 (en) | Muscle relaxant | |
| CA1231972A (en) | Substituted 1-arylamino-3-amino-2-propanols: preparation and therapeutic applications | |
| FI94860B (fi) | Menetelmä terapeuttisesti käyttökelpoisen (+)-1-/(3,4,5-trimetoksi)bentsyylioksimetyyli/-1-fenyyli-N,N-dimetyyli-n-propyyliamiinin valmistamiseksi | |
| FI61871B (fi) | Analogifoerfarande foer framstaellning av antidepressivt verkande trifluormetylsubstituerade aralkylestrar av alanin | |
| US4008329A (en) | Substituted cyclohexanes, pharmaceutical compositions containing them and method of treatment involving their use | |
| DD153682A1 (de) | Verfahren zur herstellung neuer alkanolamine | |
| FI79296B (fi) | Foerfarande foer framstaellning av 1-(2,4- diklorfenoxi)-3-(3,4-dimetoxi- -fenetylamino)-propanol-(2). |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed |
Owner name: LABORATOIRES DEBAT |